Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Orelabrutinib (ICP-022) in Relapsed/Refractory Marginal Zone Lymphoma
NCT03797456Phase 2Completed
- Sponsor
- InnoCare Pharma
- Start
- Apr 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in marginal zone lymphoma (MZL), sponsored by InnoCare Pharma. Started Apr 2019; status: completed.
02
Drugs
orelabrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT03797456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03797456.